Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging. - Wikidata - wikimedia - TriplyDB

Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging.

Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging.

http://www.wikidata.org/entity/Q39880236

about

Blood-Based Proteomic Biomarkers of Alzheimer's Disease Pathology Body fluid biomarkers in Alzheimer's disease Preferential interactions between ApoE-containing lipoproteins and Aβ revealed by a detection method that combines size exclusion chromatography with non-reducing gel-shift Association of plasma Aß peptides with blood pressure in the elderly Characterizing Aging, Mild Cognitive Impairment, and Dementia with Blood-Based Biomarkers and Neuropsychology.2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.Plasma biomarkers are associated with agitation and regional brain atrophy in Alzheimer's disease.Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease.A blood-based predictor for neocortical Aβ burden in Alzheimer's disease: results from the AIBL study.Oligomers, fact or artefact? SDS-PAGE induces dimerization of β-amyloid in human brain samples.Plasma Aβ and PET PiB binding are inversely related in mild cognitive impairment.Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study.Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI Bayesian graphical network analyses reveal complex biological interactions specific to Alzheimer's disease Epidemiology of Alzheimer disease.Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker Multiplex biomarkers in blood.Association of plasma and cortical amyloid beta is modulated by APOE ε4 status Validation of Immunoassay-Based Tools for the Comprehensive Quantification of Aβ40 and Aβ42 Peptides in Plasma.The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans.Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer's Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial.Annexin A1 restores Aβ1-42 -induced blood-brain barrier disruption through the inhibition of RhoA-ROCK signaling pathway.Plasma amyloid-β levels and prognosis in incident dementia cases of the 3-City Study Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease.Progress towards a consensus on biomarkers for Alzheimer's disease: a review of peripheral analytes.Risk factors for the progression of mild cognitive impairment to dementia.Blood Biomarkers for Alzheimer's Disease: Much Promise, Cautious Progress.Alzheimer's Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid.Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer's Dementia: Findings in Two Cohorts.Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer's disease and down syndrome.Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals.Effect of apolipoprotein E phenotype on the association of plasma amyloid β and amyloid positron emission tomography imaging in Japan.Oligomeric and fibrillar amyloid beta 42 induce platelet aggregation partially through GPVI.Physical activity and amyloid-β plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing.The clinical significance of plasma clusterin and Aβ in the longitudinal follow-up of patients with Alzheimer's disease.Study protocol of the Intense Physical Activity and Cognition study: The effect of high-intensity exercise training on cognitive function in older adults.Alterations in Acrolein Metabolism Contribute to Alzheimer's Disease.Potential blood biomarker for disease severity in the Taiwanese population with Alzheimer's disease.Plasma Aβ analysis using magnetically-labeled immunoassays and PET 18F-florbetapir binding in non-demented patients with major depressive disorder.Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies.

P2860

Q26774743-8BC42A78-CAA7-44BB-B442-CD6269D7C1FA Q26830098-0AE1D3AF-5075-49EB-BD78-24E3C25C50B3 Q28582464-51DD002F-B8C5-466B-8057-FACECD8D264C Q28740991-8037F1A1-3AF4-49AD-B93D-D899F664D59A Q30315907-ECC058D3-CB23-419B-B172-1204CFFD11A0 Q30971403-CB0DD8C5-DFA3-4004-A01D-23488ED79E14 Q33895177-73335801-56D1-4A24-B822-51A5DE30C315 Q34315258-EDF50E8E-09E3-41FA-9C69-86DB109A5D8F Q34341870-2BDD7B49-4DF5-48EA-A411-32B97F4D1C9B Q34564863-CC463866-04EE-4F96-A6B5-4DC5287A7781 Q35117068-917C9B9F-58A5-4F59-A422-A41DF6EBF196 Q35185694-BC41103F-DE7D-4B81-B49C-00DB2DC004A6 Q35821382-E537190C-ACDB-449E-8331-598EF16C9B5B Q35843380-606F3B9D-A287-4D44-A0E0-AFBC97C15FE3 Q35920548-92482169-10FC-46ED-9B9D-351C5FD2ABA5 Q36998414-B9A0D8B1-C1BF-4435-98A9-B050845B6A57 Q36998638-59D647FD-A937-49B8-B2E1-C9A2D00A2CDF Q37112462-D3B8EA0F-854A-477E-B1D1-40598A681006 Q37300264-D527BB79-C06B-4A61-B690-F564A8207B68 Q37451440-30293674-CF4C-471F-B710-01EFAE700C92 Q37589619-F3648602-01CD-4C9F-91B1-D15536EC8604 Q37591999-767A5C49-41E7-4ADF-A827-E8BAA9F036BB Q37693190-A98A6946-1977-44A3-9B9A-BAC5292C033D Q38016898-8A6E99E7-EB03-40A3-B84D-2F9EDD3DAAC3 Q38125769-7574A0FC-57BC-4FCC-A5D4-21634337C42E Q38149355-66F1D662-5B3A-40F7-B3EE-A6C6774D00A3 Q38980003-5B90A82C-3B0B-48B2-AE04-F1FDA69D76EA Q39217840-65BB8568-FA08-4BFF-A519-A1806572715B Q41097447-4747CF46-427E-4C12-9B6C-E8E18D0BA40F Q41600844-A63C78E3-5566-4E3C-9981-89FCD213F945 Q41690745-A58695AA-9C44-4B45-A044-D8B1C0D38202 Q42026115-C2F982C4-B972-402E-8CE4-AE9C89EC40B4 Q46247864-47045DF5-B197-48DA-AAD7-90EC1F135BAB Q46397777-7A4AE959-950F-4FE2-8C42-257CA4C95316 Q47155881-135A46EF-6145-47B0-8B28-16F412DC7F09 Q47164824-98D5C706-FAFB-49C7-85EA-EB136E2FB05C Q47308956-11B0923A-10A0-4732-8387-4E37A3F9188F Q48257794-459C9EA4-8112-49CE-8519-1E257655233B Q50050458-BF929891-C085-482A-8F6B-4CFF4AADC834 Q51760876-F8C986C4-9284-42E7-9206-34EBA08E442C

P2860

Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging.

http://www.wikidata.org/entity/Q39880236

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging.

@en

Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging.

@nl

type

label

Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging.

@en

Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging.

@nl

prefLabel

Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging.

@en

Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging.

@nl

P1433

Q39880236-34740915-1AA7-48E1-9CCB-940158633B23

P1476

Q39880236-C0044B3F-5799-4FBA-956B-247A0737C266

P2093

Q39880236-0703D7A7-C5B8-488D-9786-B67CB55B80F1

Q39880236-1668D9EB-0D16-475E-999B-7AD4C9E936D0

Q39880236-1A18DCF3-8874-4797-916E-E38ED19211CD

Q39880236-28B81F0C-E52D-4805-8879-BE1B44875B3F

Q39880236-428ACABB-6C2F-483F-A2BC-0A29D1988DF4

Q39880236-4584F56C-EEA6-444F-8D29-7CA3737AEA10

Q39880236-493F7DC1-3CBC-4278-9DD2-75FAA0D673D1

Q39880236-4D45B8F9-D3FB-4328-BEF0-87D436F21C18

Q39880236-59A9D0A4-B24A-4AF0-BB1E-5E41C2CA62CE

Q39880236-66181820-C993-41D0-8254-42171D72AE99

P304

Q39880236-DF221C43-EC33-4584-90FA-E4A3AED885FD

P31

Q39880236-0864A953-F08C-4B0C-8D2B-B11D5988AC0C

P356

Q39880236-E69EF018-4173-44A8-A1A8-D3454E2E6F63

P433

Q39880236-5F509882-4551-4176-83D2-FC04AA0072DC

P478

Q39880236-D3126662-625F-4529-88A5-00AB7B0C3F98

P50

Q39880236-2D3DE638-9FED-4343-91BC-E084C6C2AB37

Q39880236-3BCD4EA7-BF93-4458-AD22-3CEFF4A446AD

Q39880236-3C645BC7-8E45-41F7-8AE6-C4F1FAA5691E

Q39880236-5B42D487-04BF-4BDB-8028-AA43B7EF2B50

Q39880236-C0690C98-948E-4F8C-8017-5349DC446945

Q39880236-E9E8F2A4-5C5C-4CCC-9B65-DE8C1FC16CF1

Q39880236-FA9588AF-2985-4BAD-B3A3-19717B0BDB05

P577

Q39880236-473CF799-9E9A-4C66-8850-AD72A0FABB6B

P698

Q39880236-61DF2B09-9918-464B-B8CE-9A61F115F908

P921

Q39880236-52FF7256-0877-48AC-865F-7E4054DB2698

Q39880236-5486E481-4EB0-4ABE-8DA6-DC1CA5F17EDB

P356

JAD-2010-090249

P1433

Journal of Alzheimer's Disease

P1476

Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging.

@en

P2093

AIBL Research Group

http://www.w3.org/2001/XMLSchema#string

Alan Rembach

http://www.w3.org/2001/XMLSchema#string

Belinda Brown

http://www.w3.org/2001/XMLSchema#string

Brett Trounson

http://www.w3.org/2001/XMLSchema#string

Christopher C Rowe

http://www.w3.org/2001/XMLSchema#string

Christopher Fowler

http://www.w3.org/2001/XMLSchema#string

David Ames

http://www.w3.org/2001/XMLSchema#string

James K Lui

http://www.w3.org/2001/XMLSchema#string

Jasmin Dromey

http://www.w3.org/2001/XMLSchema#string

Jonathan Foster

http://www.w3.org/2001/XMLSchema#string

P304

1233-1242

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3233/JAD-2010-090249

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Colin L. Masters

Cassandra Szoeke

Kathryn A Ellis

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20413897

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease